Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Comments